Canlyniadau Chwilio - V.R. Peddi
- Dangos 1 - 6 canlyniadau o 6
-
1
-
2
Interim Results from an Open-Label Study of Planned Transition from Tacrolimus to Sirolimus vs Continued Tacrolimus in Renal Allograft Recipients: Cardiovascular Safety gan Hélio Tedesco‐Silva, V.R. Peddi, A. Sanchez-Fructoso, Graeme R. Russ, Brad A. Marder, C. Hahn, H. Li, Alison Flynn, Sam Schulman
Cyhoeddwyd 2012Artigo -
3
Open-Label Study of Planned Transition From Tacrolimus to Sirolimus vs Continued Tacrolimus in Renal Allograft. gan Hélio Tedesco‐Silva, V.R. Peddi, A. Sanchez-Frutuoso, Brad A. Marder, Graeme R. Russ, Alison Flynn, C. Hahn, Michael A. Tortorici, Sam Schulman
Cyhoeddwyd 2014Artigo -
4
Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data gan Yasir Qazi, David R. Shaffer, Bruce Kaplan, D.Y. Kim, Fu L. Luan, V.R. Peddi, Fuad S. Shihab, Stephen J. Tomlanovich, S. Yilmaz, Kevin McCague, Dharmesh Patel, S. Mulgaonkar
Cyhoeddwyd 2016Artigo -
5
Transition From Tacrolimus to Sirolimus vs Continued Tacrolimus in Renal Allograft Recipients: Impact On Glycemic Parameters. gan Fritz Diekmann, Hélio Tedesco‐Silva, V.R. Peddi, A. Sanchez-Fructoso, Brad A. Marder, G. R. Russ, Alison Flynn, C. Hahn, H. Li, Michael A. Tortorici, Sam Schulman
Cyhoeddwyd 2014Artigo -
6
Calcineurin-Inhibitor-Free Immunosuppression Based on the JAK Inhibitor CP-690,550: A Pilot Study in De Novo Kidney Allograft Recipients gan Stéphan Busque, Joseph R. Leventhal, Daniel C. Brennan, Steven Steinberg, Göran B. Klintmalm, T. Shah, S. Mulgaonkar, Jonathan S. Bromberg, F. Vincenti, Sundaram Hariharan, Douglas P. Slakey, V.R. Peddi, Rosemary A. Fisher, Nervin Lawendy, C. Wang, Gordon Chun‐Kau Chan
Cyhoeddwyd 2009Artigo
Offerynnau Chwilio:
Pynciau Perthynol
Internal medicine
Medicine
Tacrolimus
Transplantation
Urology
Renal function
Immunosuppression
Sirolimus
Adverse effect
Calcineurin
Everolimus
Gastroenterology
Kidney transplantation
Mycophenolic acid
Anti-thymocyte globulin
Basiliximab
Clinical endpoint
Concomitant
Confidence interval
Environmental health
Glycemic
Hazard ratio
Immunology
Insulin
Janus kinase inhibitor
Population
Randomization
Randomized controlled trial
Rheumatoid arthritis
Surgery